Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Christian Cabou, Matthew Beer, Paul Billings, Robert Lipshutz, and More

Premium

Christian Cabou, senior vice president, general counsel, and secretary at Illumina, plans to retire early in 2013, according to documents Illumina filed with the US Securities Exchange Commission. Previously, Cabou served as general counsel for GE Global Research. He holds a JD from Northwestern University School of Law, an MS in engineering management from Northwestern, an MSEE from the Conservatoire National des Arts et Metiers in Paris, and a BS from the Lycee Technique d'Etat, in Armentieres, France.


Transgenomic has appointed Matthew Beer as vice president of business development for oncology.

Beer was previously director of oncology marketing and hematology/oncology life cycle leader at Quest Diagnostics, where he developed next-gen sequencing applications. Prior to that, he was vice president of business development at Caris Life Sciences. He has also worked for Abbott, Targeted Molecular Diagnostics, and Oncotech. He holds a BS in microbiology from the University of Iowa.


Ancestry.com has appointed Paul Billings to its board of directors. Billings has also been named a member of the company's audit committee.

Billings is currently chief medical officer at Life Technologies. He also was CEO of Cellective Dx and senior vice president of Laboratory Corporation of America.


The Institute for Systems Biology has appointed Robert Lipshutz as chief business officer and senior VP for strategic partnerships.

Lipshutz spent nearly two decades at Affymetrix in various roles focusing on business development, licensing, diagnostics, and emerging markets, and most recently as senior VP for corporate development.


Pacific Biosciences' stockholders have voted to re-elect Michael Hunkapiller, Randy Livingston, and Marshall Mohr to continue serving on its board of directors as class II directors.



Joseph DiZinno
has been appointed to senior director of federal programs for IntegenX and will work out of the company's newly opened Washington, D.C.-area office, which will support IntegenX's work with federal agencies. He joins IntegenX from BAE Systems where he was technical director of homeland security and law enforcement. Previously, he was at the Federal Bureau of Investigation, where he oversaw all case-working and response units related to domestic and international criminal and terrorist cases. He also currently serves as an adjunct faculty member at George Mason University, where he teaches forensic science. He holds degrees from the University of Notre Dame and Ohio State University College of Dentistry.
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.